Rifaximin Tablets

This product is a rifamycin derivative and the first non-aminoglycoside intestinal antibiotic. This product has a strong effect and a broad antibacterial spectrum. This product has good antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus faecalis among Gram-positive aerobic bacteria, and against Salmonella, Escherichia coli, Shigella and Yersinia enterocolitica among Gram-negative aerobic bacteria. This product has high antibacterial activity against Proteus, Clostridium difficile among Gram-positive anaerobic bacteria, and Bacteroides among Gram-negative anaerobic bacteria. When using this product, there is no need to use intestinal antispasmodics (such as lopramamide, etc.) or intestinal adsorbents (such as white clay, pectin, etc.). This product acts quickly, and diarrhea will no longer occur after 2 days, and abdominal cramps, headaches, nausea, and vomiting symptoms will disappear quickly. This product is not absorbed and maintains extremely high concentrations in the intestine, but does not exist in other organs. This product is superior to neomycin, streptomycin and other aminoglycoside antibiotics in the following features: ① This product does not damage hearing function; ② It does not cause renal damage; ③ Parasitic normal flora, especially non-pathogenic enteric bacteria Escherichia coli, quickly relocate to the intestines to avoid repeated infection; ④ Intestinal mucosal inflammation may tend to disappear. Mucosal inflammation is a contraindication to the use of topical aminoglycosides, because the inflammation may be aggravated after medication.

Rifaximin. Chemical name: 4-deoxy-4-methylpyridinium [1,2-1,2] imidazole well [5,4-cyclo] rifamycin SV.

Acute and chronic intestinal infections caused by Gram-positive and negative, aerobic and anaerobic bacteria, diarrhea syndrome, diarrhea caused by changes in intestinal flora (enterocolitis, antibiotic-induced enterocolitis, traveler's diarrhea), preoperative and postoperative intestinal preventive medication, high blood ammonia, portal encephalitis, and hepatic coma.

Diarrhea: Adults and children over 12 years old take 200 mg orally, once every 6 to 8 hours, 10 to 15 mg/(kg.d); children aged 6 to 12 years old, 1 to 2 spoons every 6 to 8 hours; children aged 2 to 6 years old, 1 spoon every 6 to 8 hours. The method of preparing the oral suspension is to add water to the mark on the bottle, shake vigorously to moisten the powder. Add the rest of the water and shake vigorously again. Store at room temperature. This suspension is stable within 7 days.

1. Headaches have been reported in the central nervous system. 2. Metabolic/secretory system Patients with hepatic encephalopathy may experience weight loss and a slight increase in serum potassium and serum sodium concentrations after taking this drug. 3. Common gastrointestinal symptoms are abdominal distension, abdominal pain, nausea and vomiting. The incidence of the above symptoms is less than 1%. 4. Long-term use of large doses of the skin may cause mycosis fungoides in a very small number of patients. 5. There are reports that other drugs may cause foot edema. 6. Some patients may experience nausea after taking the drug (usually after the first dose), but the symptoms can subside quickly. Long-term use of large doses may cause mycosis fungoides in a very small number of patients.

The following patients are contraindicated: 1. Those who are allergic to this drug or rifamycin; 2. Those with intestinal obstruction; 3. Those with severe intestinal ulcerative lesions

Less than 1% of an oral dose of rifaximin is absorbed from the gastrointestinal tract, so rifaximin is unlikely to cause systemic problems due to drug interactions.

Sealed, store in a dark and dry place.

0.2g

Nanchang Feihong Pharmaceutical Co., Ltd.

• Founded in:

  1996-06-13

• Address:

  No. 388, Gaoxin 5th Road, High-tech Industrial Development Zone, Nanchang City, Jiangxi Province

• Tax NO.:

  91360100158404187P

• Registered Funds:

  10 million yuan

• Email:

  Log in to view